Direct Inhibition of Hypoxia-Inducible Transcription Factor Complex with Designed Dimeric Epidithiodiketopiperazine

Authors:
  • HWHui Wang
    Hui Wang
  • LSLajos Z. Szabó
    Lajos Z. Szabó
  • NPNathan W. Polaske
    Nathan W. Polaske
  • LHLaura K. Henchey
    Laura K. Henchey
  • SKSwati Kushal
    Swati Kushal
  • CLCsaba F. László
    Csaba F. László
  • JMJoshua Makhoul
    Joshua Makhoul
  • ZSZuohe Song
    Zuohe Song
  • EMEmmanuelle J. Meuillet
    Emmanuelle J. Meuillet

Abstract
Selective blockade of hypoxia-inducible gene expression by designed small molecules would prove valuable in suppressing tumor angiogenesis, metastasis and altered energy metabolism. We report the design, synthesis, and biological evaluation of a dimeric epidithiodiketopiperazine (ETP) small molecule transcriptional antagonist targeting the interaction of the p300/CBP coactivator with the transcription factor HIF-1α. Our results indicate that disrupting this interaction results in rapid downregulation of hypoxia-inducible genes critical for cancer progression. The observed effects are compound-specific and dose-dependent. Controlling gene expression with designed small molecules targeting the transcription factor-coactivator interface may represent a new approach for arresting tumor growth.

This publication has 47 references indexed in Scilit: